[caption id="attachment_74104" align="alignleft" width="200"] Dr. Avishek Kumar[/caption] MedicalResearch.com Interview with: Avishek Kumar, MD Board-Certified Medical Oncologist and Hematologist Edison, NJ (NYC Metro) MedicalResearch.com: What is the background for this announcement? Response: Pancreatic cancer has been one of the hardest cancers to treat in all of oncology. It is often found late. It spreads early. For decades, it has not had the kind of breakthroughs we have seen in lung cancer, melanoma, breast cancer, or other tumors. In the majority of patients with advanced pancreatic cancer, treatment has mostly meant chemotherapy. Regimens like FOLFIRINOX or gemcitabine/nab-paclitaxel can help. They can extend life. They can shrink cancer. But the benefit is often limited, and the side effects can be tough. Once the cancer grows after first-line treatment, the options get even more narrow. That is why the daraxonrasib data matter. Daraxonrasib, also known as RMC-6236, is an investigational oral targeted drug. It is designed to block active RAS signaling. That is a big deal because pancreatic cancer is one of the most RAS-driven cancers we see. Most pancreatic cancers have a KRAS mutation or another alteration in that pathway. For years, KRAS was considered "undruggable." We knew it was driving the cancer. We just did not have a good way to hit it. This new data suggests that may be changing. In previously treated advanced RAS-mutated pancreatic cancer, daraxonrasib appeared to improve median overall survival compared with standard chemotherapy. Reports have described survival of about 13.2 months versus 6.7 months. In pancreatic cancer, that is not a small finding. That is meaningful. Very meaningful.